Methods for Preventing Cardiovascular Events Through PCSK9 Reduction Using RNAi Agents
Summary
USPTO published patent application US20260108631A1 filed by inventors David KALLEND and Peter WIJNGAARD on December 22, 2025, covering methods for preventing cardiovascular events through PCSK9 reduction using RNAi agents. The application claims methods of lowering LDL cholesterol, preventing cardiac events in subjects with atherosclerotic cardiovascular disease, and treating such subjects by administering prophylactically or therapeutically effective amounts of an RNAi agent. CPC classifications span A61K (medicinal preparations containing genetic material), C07H (nucleosides/nucleotides), and C12N (mutation/genetic engineering).
“Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108631A1 for methods of preventing cardiovascular events through PCSK9 reduction using RNAi agents. The application discloses three method claims: lowering LDL cholesterol or preventing cardiac events in subjects with atherosclerotic cardiovascular disease or risk equivalents; preventing development of ASCVD; and treating subjects with ASCVD or risk equivalents — all via administering prophylactically or therapeutically effective amounts of an RNAi agent.
For parties in the pharmaceutical or biotechnology sector, this publication represents a patent landscape consideration for RNAi-based cardiovascular therapies targeting PCSK9. Competitors developing similar RNAi approaches for lipid management should assess Freedom to Operate implications. Research institutions and investors tracking cardiovascular therapeutics may reference this application as evidence of ongoing innovation in the PCSK9 inhibition space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction
Application US20260108631A1 Kind: A1 Apr 23, 2026
Inventors
David KALLEND, Peter WIJNGAARD
Abstract
Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.
CPC Classifications
A61K 48/0066 A61P 9/10 C07H 21/02 C12N 15/1137 C12Y 304/21061 C12N 2310/14 C12N 2310/315 C12N 2310/321 C12N 2310/322 C12N 2310/3515
Filing Date
2025-12-22
Application No.
19429048
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.